Gambro sales up 4%, sale to DaVita on track
This article was originally published in Clinica
Swedish renal care group Gambro reported a 4% increase in revenues to SKr3.36bn ($477m) in the first quarter, excluding the SKr3.28bn (-2%) generated by Gambro Healthcare US, which the company is selling to DaVita of California. Gambro said it was difficult to predict the timing of the US Federal Trade Commission's appraisal of the transaction, but that DaVita was in talks with the FTC and it continued to "estimate that an agreement will be reached during the second quarter".
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.